An ideal capacitor will not dissipate any power, but a real capacitor will have some power dissipation. In this work, we are going to design capacitance scaling based low power ROM design. In order to test the compatibility of this ROM design with latest i7 Processor, we are operating this ROM with frequencies (2.9GHz, 3.3GHz, 3.6GHz, 3.8GHz and 4.0GHz) supported by i7 processor.By using different capacitance there comes is reduction in I/O Power and Total power but not in other Powers like Clock, and Leakage (almost negligible). When capacitance goes from 30pF to 5pF, there is a saving of 28.12% occur in I/O Power, saving of 0.2% occur in Leakage Power, there will be a saving of 11.54% occur in Total Power. This design is implemented on Virtex-5 FPGA using Xilinx ISE and Verilog.

—Thermal aware design is currently gaining importance in VLSI research domain. In this work, we are going to design thermal aware energy efficient ROM on Virtex-5 FPGA. Ambient Temperature, airflow, and heat sink profile play a significant role in thermal aware hardware design life cycle. Ambient temperature is a temperature of surroundings. Airflow is measured in Linear Feet per Minute (LFM). Medium profile and high profile are two different heat sink profile available in XPower analyzer.When frequency goes from 4.0GHz to 1.0GHz, there is 21.8% reduction in clock power, 75% reduction in I/O Power, 35.6% reduction in leakage power and 53.8% reduction in total power at the same frequency.

No abstract

Background: To investigate the efficacy and safety of Pulse steroid therapy in the management of Infantile facial hemangioma in five subjects.Methods: Consecutive patients who presented with facial hemangioma were prospectively enrolled in this study between January 2014 till August 2017. All subjects underwent treatment with 30mg/kg/day I/V methyl prednisolone for 6days and then weekly for 6weeks and then followed by oral daily dosing. All subjects underwent systemic, and radiologic evaluations before treatment and at periodic intervals after starting therapy. Side effects from therapy were also evaluated.Results: Five subjects under 6 months of age, with facial hemangioma were enrolled in this study. After hospital admission, I/V steroid therapy was initiated in all subjects under monitoring by a pediatric cardiologist. Subsequent oral therapy after 6 weeks was performed with periodic out-patient monitoring. All subjects had excellent response to treatment, with regression of facial hemangioma. There were no side effects from therapy.Conclusions: I/V methyl prednisolone pulse steroid therapy for facial hemangioma was effective in all the five subjects.